Bipolar Disorders

Valbenazine significantly reduced involuntary movements associated with tardive dyskinesia in patients with primary mood disorders, at both 6 weeks and 48 weeks after beginning the treatment, according to a published analysis.


The strength of a person’s handgrip was associated with their performance on multiple cognitive tasks, researchers found in a review of data on more than 110,000 people.

In an analysis of data on more than 110,000 people, researchers found an association between which physical fitness measure and cognitive functioning? Get the answer and more information here.

EEG delta/alpha frequency activity can be used to differentiate patients with schizophrenia, bipolar disorder, and methamphetamine-induced psychotic disorder, researchers from South Africa report.

Vladimir Maletic

Dextromethorphan (DM) has long been in use as an ingredient in cough medicines. More recently, in combination with quinidine (DM/Q), it has been approved as a treatment for pseudobulbar affect. But what does the research say about using it to treat mood disorders?

Women with polycystic ovary syndrome (PCOS) are at increased risk of depression, anxiety, bipolar disorder, and eating disorders, according to a large case-control study from the UK.



As a client/patient being treated for a behavioral health problem, you are asked to do something that very few ever do successfully. You are asked to change.

The question of spirituality has been at the center of my recovery with bipolar disorder, addiction, child abuse, and persistent trauma. How do you approach spirituality with your clients?

I woke up medicated, in four-point restraints, in the quiet room of a private psychiatric hospital in 1995. My life was instantly tethered to my new pharmaceutical regimen.



Andrew Cutler, MD; Stanley Caroff, MD; Caroline Tanner, MD, PhD; William Lenderking, PhD; Karen Yeomans, BSc; Huda Shalhoub, PhD; Linda Ross, MPH; Chuck Yonan, PharmD
Traci Aladeen, PharmD; Emily Lewandowski, PharmD; Michelle Rainka, PharmD; Erica Westphal, BA/BS; Jonathan Beecher, N/A; Francis Gengo, PharmD; Horacio Capote
Eve Hershberger, MD, PhD; Jaskaran Grewal, MD; Lynn George, ARNP
Anita Loughlin, PhD; Nancy Lin, ScD; Victor Abler, DO; Benjamin Carroll, PharmD
Charles L. Raison, MD; Andrei Pikalov, MD, PhD; Cynthia Siu, PhD; Joyce Tsai, PhD; Kenneth Koblan, PhD; Antony Loebel, MD



Timothy Wilens, MD, and Charles Raison, MD, discuss how clinicians can distinguish bipolar disorder from attention deficit hyperactivity disorder (ADHD) in children. They also explore which therapies might be appropriate.

Terence Ketter, MD, talks about why clinicians tend to be therapeutic optimists and patients tend to be side effects pessimists. Resolving these differences and individualizing treatment is important to the therapeutic alliance.